Cg Oncology, INC Form 4 insider transactions

CG Oncology Director Leonard E. Post exercised stock options and subsequently sold 1,000 shares of common stock for $28.00 per share.

CG Oncology Director Leonard Post exercised 2,000 stock options at $0.60 per share and simultaneously sold the same number of shares at $28.00 per share, as part of a pre-arranged trading plan.

CG Oncology, Inc. Director Susan E. Graf was granted 24,165 stock options with an exercise price of $26.63, vesting monthly over a year, as part of her compensation.

CG Oncology, Inc. Director Leonard E. Post was granted 24,165 stock options with an exercise price of $26.63, vesting monthly over one year.

CG Oncology, Inc. has granted 24,165 stock options to Director Hong Fang Song, with an exercise price of $26.63 per share, aligning executive incentives with shareholder value.

CG Oncology, Inc. Director James Mulay was granted 24,165 stock options with an exercise price of $26.63 per share, vesting monthly over a year or upon the next annual meeting.

CG Oncology, Inc. Director Brian Guan-Chyun Liu was granted 24,165 stock options with an exercise price of $26.63, vesting monthly over a year, as disclosed in a recent SEC Form 4 filing.

CG Oncology, Inc. Director and 10% Owner Victor Edward Tong Jr. was granted 24,165 stock options with an exercise price of $26.63, vesting monthly over one year.

Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.

Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.

Arthur Kuan, CEO of CG Oncology, Inc., reports the acquisition of employee stock options.

Ambaw Bellete, President and COO of CG Oncology, Inc., reports the acquisition of stock options.

Vijay Kasturi, Chief Medical Officer of CG Oncology, Inc., was granted employee stock options on April 15, 2025.

Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., reports the acquisition of employee stock options.

CFO of CG Oncology, Corleen M. Roche, reports acquisition of employee stock options.

Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.

Director Leonard Post exercised stock options and sold shares of CG Oncology under a pre-arranged Rule 10b5-1 trading plan.

CG Oncology director Leonard Post exercised stock options and sold 1,000 shares of common stock on January 13, 2025, according to a recent SEC filing.

A CG Oncology director, Hong Fang Song, indirectly sold 700,000 shares of common stock at $28 per share through Charming Jade Limited as part of a public offering.

CG Oncology director Leonard Post exercised stock options and sold 1,000 shares of common stock on December 16, 2024, according to a recent SEC filing.

CG Oncology director Leonard Post executed a series of stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Corleen M. Roche, CFO of CG Oncology, Inc., was granted stock options for 93,600 shares on October 4, 2024, according to a Form 4 filing with the SEC.

Leonard E. Post, a director of CG Oncology, Inc., acquired stock options for 15,600 shares of common stock on October 4, 2024.

Director Susan E. Graf acquired stock options for 15,600 shares of CG Oncology common stock on October 4, 2024.

Brian Guan-Chyun Liu, a director at CG Oncology, acquired stock options for 15,600 shares of common stock on October 4, 2024.

Victor Edward Tong Jr., a director at CG Oncology, Inc., acquired stock options for 15,600 shares at an exercise price of $36.63 on October 4, 2024.

Vijay Kasturi, Chief Medical Officer of CG Oncology, reports the acquisition of stock options for 132,600 shares of common stock.

Director Hong Fang Song acquired stock options in CG Oncology, Inc. on October 4, 2024.

Director James Mulay acquired stock options in CG Oncology, Inc. on October 4, 2024.

Ambaw Bellete, President and COO of CG Oncology, Inc., was granted stock options for 175,500 shares of common stock at an exercise price of $36.63 on October 4, 2024.